Skip to main content

Table 3 Patients with CMV disease

From: A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation

UPN ASSAY DAYS FROM TRANSPLANT
   -7 0 +7 +14 +21 +28 +35 +42 +49 +56 +63 +70 +77 +84 +91 +100
0133.1 Pp65 Ag - • - • - • ND - • - • - • - • - • -** • - - - - - 2
  Plasma PCR - • - • - • ND - • - • - • - • - • -** • - - - - - -
0136.1 pp65 Ag - • - • - • - • - • - • - • - • 400** • 83 1 5 2 - 4 -
  Plasma PCR - • - • - • - • - • - • - • - • 22600** • 12300 8810 6000 1290 - - -
0138.1 pp65 Ag - • - • - • 7• -** - - - • 60- • 23 4 - - - - 19
  Plasma PCR - • - • - • - • -** - - - •- 1230- • 4070 16700 2240 - - 758 2250
  1. UPN: unique patient number; Ag: antigenemia; PCR: polymerase chain reaction; ND: not done; NE: not evaluate; -: negative result; **: CMV disease. Dots represent samples of patients not on pre-emptive therapy.
  2. All patients developed intestinal CMV disease and UPN 0136.1 died on day + 111 for CMV disease associated with aGVHD.